Biography for Carly Helfand
Carly Helfand, News Editor
Carly Helfand is a news editor with Fierce's life sciences group, writing for FiercePharma, FiercePharmaMarketing and FierceVaccines. Carly got her start covering pharma while earning her master’s at Northwestern University’s Medill School of Journalism, where she concentrated in business reporting. She has completed journalism projects on four continents, and her work has appeared in various outlets such as The Boston Globe, The Washington Post’s “Wonkblog” and Cape Town’s Weekend Argus. Carly prefers watching pro hockey to nearly everything. She also plays the Irish fiddle. You can contact her at firstname.lastname@example.org and follow her on Twitter at @CarlyHFierce.
- Contact Carly
- Follow Carly on Google+
Articles by Carly Helfand
In conventional conjugate vaccines, proteins act as carriers for polysaccharides that induce an immune response. But what if those proteins could induce an immune response, too?
We have a winner. In a two-horse race to grab the first-ever U.S. approval for a meningitis B vaccine, Pfizer has emerged victorious, nabbing the FDA's blessing Wednesday.
Novartis' 8-year foray into vaccines is officially coming to a close. After divesting the bulk of its unit to GlaxoSmithKline in an April deal, the pharma giant Sunday announced it had agreed to sell its flu shot business to Australia's CSL. And with that, it'll make its exit from a field that's given it trouble since its Chiron buyout in 2006.
Cancer vaccine developers have seen their fair share of disappointments, and failures have spurred some companies to test their treatments in smaller patient subpopulations. Now, researchers are narrowing their focus even further as they gear up to trial personalized cancer vaccines.
Could oral vaccines shake up the flu shot market? Vaxart's Ph I says maybe
Flu shots are a driving sales force for more than a couple vaccine players. But could an oral alternative disrupt the flu vaccine market down the line?
To help show Americans just how important its flu vaccines are, Novartis has teamed up with entertainer Nick Cannon, who's advising consumers to prepare for flu season by getting their shots and stocking up on the Swiss pharma's over-the-counter remedy, Theraflu.
GlaxoSmithKline's vaccines unit will be getting a new look come next year, when it's expected to absorb the bulk of Novartis' vaccines lineup it bought for $7.1 billion back in April. It'll have some new management, too, with Moncef Slaoui in the chairman's role. And judging from the pharma giant's Q3 results, some change for the unit could be a good thing.
Sanofi's Pentacel, which protects children against 5 serious diseases, nabbed the No. 3 spot on the world's list of best-selling vaccines last year. Whether an investigational 6-in-1 combo from the French drugmaker and partner Merck can eventually match its success remains to be seen, but the pair is now one step closer to finding out.
Back in May, Johnson & Johnson's Janssen and California-based Aduro Biotech inked a $365 million deal centered on the former's vaccine technology as a treatment for prostate cancer. But J&J is convinced Aduro's platform has the potential to bolster its oncology pipeline in other areas, too.
Selecta Biosciences and the Juvenile Diabetes Research Foundation are widening their 2011 research collaboration for a Type 1 diabetes vaccine--and bringing in a little Big Pharma muscle, too.